245 related articles for article (PubMed ID: 24182612)
1. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.
Lansdorp-Vogelaar I; Sharp L
Best Pract Res Clin Gastroenterol; 2013 Dec; 27(6):933-47. PubMed ID: 24182612
[TBL] [Abstract][Full Text] [Related]
2. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity.
Teng AM; Kvizhinadze G; Nair N; McLeod M; Wilson N; Blakely T
BMC Infect Dis; 2017 Feb; 17(1):156. PubMed ID: 28219322
[TBL] [Abstract][Full Text] [Related]
3. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials.
Parsonnet J; Harris RA; Hack HM; Owens DK
Lancet; 1996 Jul; 348(9021):150-4. PubMed ID: 8684154
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a markov model.
Xie F; Luo N; Lee HP
World J Gastroenterol; 2008 May; 14(19):3021-7. PubMed ID: 18494053
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Mason J; Axon AT; Forman D; Duffett S; Drummond M; Crocombe W; Feltbower R; Mason S; Brown J; Moayyedi P;
Aliment Pharmacol Ther; 2002 Mar; 16(3):559-68. PubMed ID: 11876711
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori?
Harris RA; Owens DK; Witherell H; Parsonnet J
Helicobacter; 1999 Jun; 4(2):69-76. PubMed ID: 10382118
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter Pylori and Gastric Cancer: Clinical Aspects.
Song ZQ; Zhou LY
Chin Med J (Engl); 2015 Nov; 128(22):3101-5. PubMed ID: 26608993
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation.
Roderick P; Davies R; Raftery J; Crabbe D; Pearce R; Patel P; Bhandari P
J Med Screen; 2003; 10(3):148-56. PubMed ID: 14561268
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed?
Park JY; Forman D; Greenberg ER; Herrero R
Curr Oncol Rep; 2013 Dec; 15(6):517-25. PubMed ID: 24101366
[TBL] [Abstract][Full Text] [Related]
11. Screening and eradication of
Liou JM; Malfertheiner P; Lee YC; Sheu BS; Sugano K; Cheng HC; Yeoh KG; Hsu PI; Goh KL; Mahachai V; Gotoda T; Chang WL; Chen MJ; Chiang TH; Chen CC; Wu CY; Leow AH; Wu JY; Wu DC; Hong TC; Lu H; Yamaoka Y; Megraud F; Chan FKL; Sung JJ; Lin JT; Graham DY; Wu MS; El-Omar EM;
Gut; 2020 Dec; 69(12):2093-2112. PubMed ID: 33004546
[TBL] [Abstract][Full Text] [Related]
12. Screening to Identify and Eradicate Helicobacter pylori Infection in Teenagers in Japan.
Akamatsu T; Okamura T; Iwaya Y; Suga T
Gastroenterol Clin North Am; 2015 Sep; 44(3):667-76. PubMed ID: 26314676
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan.
Kowada A
Epidemiol Infect; 2018 Oct; 146(14):1834-1840. PubMed ID: 30056808
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
15. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model.
Han Y; Yan T; Ma H; Yao X; Lu C; Li Y; Li L
Dig Dis Sci; 2020 Jun; 65(6):1679-1688. PubMed ID: 31673902
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects.
Sonnenberg A
Am J Gastroenterol; 1996 Sep; 91(9):1773-7. PubMed ID: 8792696
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases.
Chen Q; Liang X; Long X; Yu L; Liu W; Lu H
Helicobacter; 2019 Apr; 24(2):e12563. PubMed ID: 30672082
[TBL] [Abstract][Full Text] [Related]
18. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration.
Schulz TR; McBryde ES; Leder K; Biggs BA
PLoS One; 2014; 9(9):e108610. PubMed ID: 25268809
[TBL] [Abstract][Full Text] [Related]
19. Population screening and treatment of Helicobacter pylori infection.
O'Connor A; O'Morain CA; Ford AC
Nat Rev Gastroenterol Hepatol; 2017 Apr; 14(4):230-240. PubMed ID: 28053340
[TBL] [Abstract][Full Text] [Related]
20. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis.
Lee YC; Chiang TH; Chou CK; Tu YK; Liao WC; Wu MS; Graham DY
Gastroenterology; 2016 May; 150(5):1113-1124.e5. PubMed ID: 26836587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
